A recent study suggests that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional diet and exercise programs.
Research printed in a leading medical journal demonstrates that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals using these treatments should be informed of the risk of fast rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about 18 months.
Analyzing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
Researchers point out that individuals who shed pounds through dieting typically experience a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Nutrition scientists believe the mechanism of the drugs is key to understanding the accelerated regain.
The injections imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement means hunger is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts contend that, considering the high risk of relapse, the treatment should be considered ongoing.
This opinion is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," similar to managing diseases like hypertension.
Patient Experiences
Users who have come off the medication report a powerful return of cravings.
"I experienced a trigger flipping and you become ravenous," described an individual.
This challenge is compounded if patients have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Survey data show that a significant number of people in the UK have used these injections in the past year, with desire being substantial.
- Use is more common among females than men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, experts emphasize that while these medications are potent tools for weight loss, they are not a magic solution and maintained weight loss relies on combined behavioural changes.
